These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 30933266

  • 1. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S, Hofmann-Thiel S, Merker M, Krieger D, Niemann S, Rüssmann H, Schönfeld N, Hoffmann H, Kranzer K.
    Clin Infect Dis; 2019 Sep 13; 69(7):1229-1231. PubMed ID: 30933266
    [Abstract] [Full Text] [Related]

  • 2. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS, Kim KJ, Choi H, Lee SH.
    Ann Lab Med; 2018 Nov 13; 38(6):563-568. PubMed ID: 30027700
    [Abstract] [Full Text] [Related]

  • 3. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.
    Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H.
    Antimicrob Agents Chemother; 2017 Oct 13; 61(10):. PubMed ID: 28739779
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.
    Ahmad Khosravi N, Sirous M, Khosravi AD, Saki M.
    J Clin Lab Anal; 2024 Aug 13; 38(15-16):e25091. PubMed ID: 39431709
    [Abstract] [Full Text] [Related]

  • 6. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
    Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC.
    N Engl J Med; 2015 Nov 12; 373(20):1986-8. PubMed ID: 26559594
    [Abstract] [Full Text] [Related]

  • 7. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.
    Emerg Infect Dis; 2017 Oct 12; 23(10):1718-21. PubMed ID: 28758888
    [Abstract] [Full Text] [Related]

  • 8. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M, Lingtsang RD, Tiberi S, Enwerem M, D'Ambrosio L, Sadutshang TD, Centis R, Migliori GB.
    Eur Respir J; 2016 Sep 12; 48(3):935-8. PubMed ID: 27288039
    [Abstract] [Full Text] [Related]

  • 9. Bedaquiline plus delamanid for XDR tuberculosis.
    Lachâtre M, Rioux C, Le Dû D, Fréchet-Jachym M, Veziris N, Bouvet E, Yazdanpanah Y.
    Lancet Infect Dis; 2016 Mar 12; 16(3):294. PubMed ID: 26973310
    [No Abstract] [Full Text] [Related]

  • 10. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
    Yoshiyama T, Takaki A, Aono A, Mitarai S, Okumura M, Ohta K, Kato S.
    Clin Infect Dis; 2021 Dec 16; 73(12):2329-2331. PubMed ID: 32730621
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E, Ferlazzo G, Hewison C, De Azevedo V, Isaakidis P.
    Lancet Infect Dis; 2019 May 16; 19(5):470. PubMed ID: 31034392
    [No Abstract] [Full Text] [Related]

  • 16. Bedaquiline and delamanid in tuberculosis.
    Esposito S, Bianchini S, Blasi F.
    Expert Opin Pharmacother; 2015 May 16; 16(15):2319-30. PubMed ID: 26293803
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.
    Int J Tuberc Lung Dis; 2016 Feb 16; 20(2):177-86. PubMed ID: 26792469
    [Abstract] [Full Text] [Related]

  • 20. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.
    Lancet Infect Dis; 2018 May 16; 18(5):536-544. PubMed ID: 29452942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.